Somewhat Favorable News Coverage Somewhat Unlikely to Impact ProNAi Therapeutics (NASDAQ:SRRA) Share Price

Media stories about ProNAi Therapeutics (NASDAQ:SRRA) have been trending somewhat positive on Saturday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ProNAi Therapeutics earned a news impact score of 0.05 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.8359535692052 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern Sentiment’s rankings:

Shares of ProNAi Therapeutics (SRRA) traded up 1.90% during midday trading on Friday, reaching $2.15. The company’s stock had a trading volume of 647,599 shares. The company’s market cap is $112.38 million. The company’s 50-day moving average price is $1.70 and its 200-day moving average price is $1.43. ProNAi Therapeutics has a 12 month low of $1.10 and a 12 month high of $2.25.

ProNAi Therapeutics (NASDAQ:SRRA) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.01. On average, equities analysts anticipate that ProNAi Therapeutics will post ($0.89) EPS for the current fiscal year.

Several equities research analysts have issued reports on SRRA shares. Zacks Investment Research raised ProNAi Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Jefferies Group LLC reaffirmed a “hold” rating on shares of ProNAi Therapeutics in a research note on Thursday, July 27th. Finally, ValuEngine raised ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $4.00.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact ProNAi Therapeutics (NASDAQ:SRRA) Share Price” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at

ProNAi Therapeutics Company Profile

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Insider Buying and Selling by Quarter for ProNAi Therapeutics (NASDAQ:SRRA)

Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply